Please read National COVID Cohort Collaborative’s article in the JAMA Network titled, “Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative.“
As of the middle of December 2020, SARS-CoV-2 had infected more than 70 million people and caused more than 1.6 million deaths worldwide. SARS-CoV-2 can cause COVID-19, a condition characterized by pneumonia, hyperinflammation, hypoxemic respiratory failure, a prothrombotic state, cardiac dysfunction, substantial mortality, and persistent morbidity in some survivors. Few therapeutic interventions authorized by the US Food and Drug Administration are available, and vaccine deployment has been slow. Progress in COVID-19 research has been slowed by a lack of broad access to clinical data. Investigators in the United Kingdom and Denmark have performed person-level analytical analyses across their respective populations to inform health care delivery, medication decisions, and national interventions, but the US has not had this capacity. A large, multicenter, representative clinical data set has been desperately needed by US practitioners, scientists, health care systems, and policymakers to develop predictive and diagnostic computational tools and to inform critical decisions. To read the full article.
Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, Bradwell KR, Bremer C, Byrd JB, Denham A, DeWitt PE, Gabriel D, Garibaldi BT, Girvin AT, Guinney J, Hill EL, Hong SS, Jimenez H, Kavuluru R, Kostka K, Lehmann HP, Levitt E, Mallipattu SK, Manna A, McMurry JA, Morris M, Muschelli J, Neumann AJ, Palchuk MB, Pfaff ER, Qian Z, Qureshi N, Russell S, Spratt H, Walden A, Williams AE, Wooldridge JT, Yoo YJ, Zhang XT, Zhu RL, Austin CP, Saltz JH, Gersing KR, Haendel MA, Chute CG; National COVID Cohort Collaborative (N3C) Consortium. JAMA Netw Open. 2021 Jul 1;4(7):e2116901. PMID: 34255046 PMCID: PMC8278272 DOI: 10.1001/jamanetworkopen.2021.16901